Scroll

ziprasidone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2865	146939-27-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ziprasidone zaprasidone ziprasidone hydrochloride ziprasidone mesylate geodon ziprasidone HCl ziprasidone mesilate	a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone Molecular weight: 412.94 Formula: C21H21ClN4OS CLOGP: 4.86 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 48.47 ALOGS: -4.76 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ziprasidone
zaprasidone
ziprasidone hydrochloride
ziprasidone mesylate
geodon
ziprasidone HCl
ziprasidone mesilate

a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone

Molecular weight: 412.94
Formula: C21H21ClN4OS
CLOGP: 4.86
LIPINSKI: 0
HAC: 5
HDO: 1
TPSA: 48.47
ALOGS: -4.76
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
80	mg	O
40	mg	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	60 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
MRTD (Maximum Recommended Therapeutic Daily Dose)	6.36 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
CL (Clearance)	5.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.10 hours	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
Vd (Volume of distribution)	1 L/kg	Lombardo F, Berellini G, Obach RS
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.21 mg/mL	Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma)	0.00 %	Lombardo F, Berellini G, Obach RS

Showing 1 to 9 of 9 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Feb. 5, 2001	FDA	PFIZER

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dystonia	1344.29	19.55	376	17796	13443	63457407
Blood prolactin abnormal	1336.16	19.55	280	17892	2799	63468051
Sexual dysfunction	1331.99	19.55	297	17875	4062	63466788
Anosognosia	1093.65	19.55	239	17933	2957	63467893
Disturbance in social behaviour	1024.61	19.55	236	17936	3757	63467093
Sedation	1012.90	19.55	390	17782	38419	63432431
Metabolic disorder	934.55	19.55	241	17931	6262	63464588
Dyskinesia	930.15	19.55	348	17824	31654	63439196
Personality change	846.24	19.55	226	17946	6747	63464103
Suicide attempt	726.33	19.55	352	17820	60566	63410284

Showing 1 to 10 of 150 entries

Previous1 2 3 4 5…15Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dystonia	465.86	22.26	169	12949	10676	34933137
Akathisia	403.64	22.26	141	12977	7968	34935845
Antipsychotic drug level below therapeutic	329.44	22.26	92	13026	2455	34941358
Therapeutic product effect variable	309.84	22.26	87	13031	2369	34941444
Disinhibition	307.95	22.26	92	13026	3134	34940679
Neuroleptic malignant syndrome	307.64	22.26	145	12973	17789	34926024
Euphoric mood	307.45	22.26	105	13013	5536	34938277
Dyskinesia	302.97	22.26	154	12964	22259	34921554
Obsessive-compulsive disorder	297.13	22.26	102	13016	5462	34938351
Anosognosia	287.98	22.26	68	13050	905	34942908

Showing 1 to 10 of 107 entries

Previous1 2 3 4 5…11Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood prolactin abnormal	1471.77	18.92	314	23490	3287	79717297
Dystonia	1411.40	18.92	435	23369	20964	79699620
Sexual dysfunction	1355.83	18.92	339	23465	7424	79713160
Anosognosia	1240.28	18.92	275	23529	3489	79717095
Disturbance in social behaviour	1143.29	18.92	271	23533	4699	79715885
Sedation	1048.41	18.92	439	23365	51456	79669128
Dyskinesia	1024.12	18.92	414	23390	44359	79676225
Metabolic disorder	1001.62	18.92	276	23528	8894	79711690
Personality change	914.88	18.92	263	23541	9907	79710677
Suicide attempt	760.35	18.92	407	23397	82525	79638059

Showing 1 to 10 of 192 entries

Previous1 2 3 4 5…20Next

FDA Adverse Event Reporting System (Pediatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dacryostenosis congenital	39.35	29.74	8	117	8	89659
Opisthotonus	35.79	29.74	8	117	17	89650

Showing 1 to 2 of 2 entries

Previous1Next

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	N05AE04	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Indole derivatives
CHEBI has role	CHEBI:35471	psychotropic drugs
CHEBI has role	CHEBI:35476	neuroleptics
CHEBI has role	CHEBI:37956	antihistamines
CHEBI has role	CHEBI:48279	serotonin antagonists
CHEBI has role	CHEBI:48561	dopaminergic antagonists
CHEBI has role	CHEBI:48876	muscarinic antagonists
FDA EPC	N0000175430	Atypical Antipsychotic
MeSH PA	D014150	Antipsychotic Agents
MeSH PA	D002491	Central Nervous System Agents

Showing 1 to 10 of 18 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Mixed bipolar I disorder	indication	16506000	DOID:3312
Schizophrenia	indication	58214004	DOID:5419
Bipolar disorder in remission	indication	85248005
Bipolar affective disorder, current episode manic	indication	191618007
Agitation associated with Schizophrenia	indication
Bipolar affective disorder, current episode depression	off-label use	191627008	DOID:3312
Depression Treatment Adjunct	off-label use
Tachyarrhythmia	contraindication	6285003
Suicidal thoughts	contraindication	6471006
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464

Showing 1 to 10 of 44 entries

Previous1 2 3 4 5Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.26	acidic
pKa2	7.35	Basic
pKa3	0.27	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 20MG BASE	GEODON	VIATRIS	N020825	Feb. 5, 2001	RX	CAPSULE	ORAL	Jan. 28, 2025	INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
EQ 40MG BASE	GEODON	VIATRIS	N020825	Feb. 5, 2001	RX	CAPSULE	ORAL	Jan. 28, 2025	INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
EQ 60MG BASE	GEODON	VIATRIS	N020825	Feb. 5, 2001	RX	CAPSULE	ORAL	Jan. 28, 2025	INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
EQ 80MG BASE	GEODON	VIATRIS	N020825	Feb. 5, 2001	RX	CAPSULE	ORAL	Jan. 28, 2025	INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES

Showing 1 to 4 of 4 entries

Previous1Next

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	ANTAGONIST	Ki	8.32	WOMBAT-PK	CHEMBL
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN	ANTAGONIST	Ki	9.40	WOMBAT-PK	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN		Ki	5.30	PDSP
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	8.02	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.30	WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	6.92	WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		IC50	7	WOMBAT-PK
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	7.36	PDSP
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		EC50	8.47	WOMBAT-PK
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.57	PDSP

Showing 1 to 10 of 43 entries

Previous1 2 3 4 5Next

External reference:

Show entries

Search:

ID	Source
009104	NDDF
009105	NDDF
009579	NDDF
115698	RXNORM
129479007	SNOMEDCT_US
138982-67-9	SECONDARY_CAS_RN
16791	MMSL
187736	MMSL
199191-69-0	SECONDARY_CAS_RN
331404	MMSL

Showing 1 to 10 of 34 entries

Previous1 2 3 4Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Geodon	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0052	CAPSULE	20 mg	ORAL	NDA	32 sections
Geodon	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0052	CAPSULE	20 mg	ORAL	NDA	32 sections
Geodon	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0052	CAPSULE	20 mg	ORAL	NDA	32 sections
Geodon	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0054	CAPSULE	40 mg	ORAL	NDA	32 sections
Geodon	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0054	CAPSULE	40 mg	ORAL	NDA	32 sections
Geodon	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0054	CAPSULE	40 mg	ORAL	NDA	32 sections
Geodon	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0056	CAPSULE	60 mg	ORAL	NDA	32 sections
Geodon	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0056	CAPSULE	60 mg	ORAL	NDA	32 sections
Geodon	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0056	CAPSULE	60 mg	ORAL	NDA	32 sections
Geodon	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0058	CAPSULE	80 mg	ORAL	NDA	32 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next